TOKYO -- Pharmaceutical companies in Japan and abroad are racing to develop cancer immunotherapies, seeking shares of that growth market following the first such drug's revolutionary debut.
Business
TOKYO -- Pharmaceutical companies in Japan and abroad are racing to develop cancer immunotherapies, seeking shares of that growth market following the first such drug's revolutionary debut.
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.